Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.62 Analyst target: $8.00 Upside: 393.83%
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer, liver and inflammatory diseases, COVID-19, and erectile dysfunction. The company is headquartered in Petah-Tikva, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.